All In Biotech

Drug Trial Radar · NCT07662044

A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Alone or in Combination With Dapagliflozin Compared With Placebo in Adults With Type 2 Diabetes Mellitus

A Randomized, Double-blind, Parallel-group Phase III Study to Evaluate the Efficacy, Safety, and Tolerability of Elecoglipron Alone or in Combination With Dapagliflozin Compared With Placebo in Adults With Type 2 Diabetes Mellitus (Eluminate-1)

Last checked: Nov 19, 2026Latest source record: Aug 31, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 800 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

800

Planned (sponsor's estimate)

Start

Jul 6, 2026

Primary completion

Jul 14, 2028

Study completion Jul 14, 2028

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
First posted
Jun 23, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the efficacy, safety, and tolerability of elecoglipron alone or in combination with dapagliflozin compared with placebo in adults with type 2 diabetes mellitus (T2DM) inadequately managed with lifestyle management alone or treated with other background glucose-lowering medication.

Conditions

  • Type 2 Diabetes Mellitus

Interventions

  • ElecoglipronDrug

    Elecoglipron is administered orally once daily.

  • DapagliflozinDrug

    Dapagliflozin administered orally once daily.

  • Elecoglipron-matched placeboDrug

    A placebo matching elecoglipron, administered orally once daily.

  • Dapagliflozin-matched placeboDrug

    A placebo matching dapagliflozin, administered orally once daily.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from baseline in Hemoglobin A1c (HbA1c)Time frame: Baseline to Week 40

Locations

149 sites in 13 countries. Site status is shown where the registry gives one.

  • Research Site

    Birmingham, Alabama · Not yet recruiting

  • Research Site

    Daphne, Alabama · Not yet recruiting

  • Research Site

    Lomita, California · Not yet recruiting

  • Research Site

    Los Alamitos, California · Not yet recruiting

  • Research Site

    San Diego, California · Suspended

  • Research Site

    Walnut Creek, California · Suspended

  • Research Site

    Englewood, Colorado · Not yet recruiting

  • Research Site

    Bridgeport, Connecticut · Not yet recruiting

  • Research Site

    Jacksonville, Florida · Not yet recruiting

  • Research Site

    Orlando, Florida · Not yet recruiting

  • Research Site

    Conyers, Georgia · Not yet recruiting

  • Research Site

    Decatur, Georgia · Not yet recruiting

  • Research Site

    Hinesville, Georgia · Not yet recruiting

  • Research Site

    El Dorado, Kansas · Not yet recruiting

  • Research Site

    Newton, Kansas · Not yet recruiting

  • Research Site

    Lexington, Kentucky · Not yet recruiting

  • Research Site

    Covington, Louisiana · Not yet recruiting

  • Research Site

    Bowie, Maryland · Not yet recruiting

  • Research Site

    Southfield, Michigan · Not yet recruiting

  • Research Site

    Kansas City, Missouri · Not yet recruiting

  • Research Site

    St Louis, Missouri · Not yet recruiting

  • Research Site

    Las Vegas, Nevada · Not yet recruiting

  • Research Site

    Anderson, South Carolina · Not yet recruiting

  • Research Site

    Knoxville, Tennessee · Not yet recruiting

  • Research Site

    Fort Worth, Texas · Suspended

  • Research Site

    Irving, Texas · Not yet recruiting

  • Research Site

    Renton, Washington · Not yet recruiting

  • Research Site

    Buenos Aires, Argentina · Not yet recruiting

  • Research Site

    Caba, Argentina · Not yet recruiting

  • Research Site

    CABA, Argentina · Not yet recruiting

  • Research Site

    Ciudad de Buenos Aires, Argentina · Not yet recruiting

  • Research Site

    Mar del Plata, Argentina · Not yet recruiting

  • Research Site

    San Nicolás, Argentina · Not yet recruiting

  • Research Site

    San Vicente, Argentina · Not yet recruiting

  • Research Site

    Santa Fe, Argentina · Not yet recruiting

  • Research Site

    Baotou, China · Not yet recruiting

  • Research Site

    Binzhou, China · Not yet recruiting

  • Research Site

    Cangzhou, China · Not yet recruiting

  • Research Site

    Changsha, China · Not yet recruiting

  • Research Site

    Chengdu, China · Not yet recruiting

Showing 40 of 149 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.